文献速递真菌感染新发突发、热带与寄生虫病

伏立康唑联合特比萘芬治疗侵袭性Lomentospora prolificans感染

Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019.
PubMed 文献 · Clin Microbiol Infect · 2020-01-20

该研究基于FungiScope®登记库2008-2019年数据,回顾性分析8个国家41例侵袭性L. prolificans感染患者。联合抗真菌治疗与28天生存率提高相关(15/24对4/16,p 0.027),伏立康唑联合特比萘芬方案治疗成功率呈更高趋势(10/16,63%,95%CI 35%-85%),但总体病死率仍高(21/40,53%)。

要点

  • 联合抗真菌治疗与更高的28天生存率相关(p 0.027)。
  • 伏立康唑联合特比萘芬治疗成功率63%(95%CI 35%-85%),呈优于其他方案趋势(p 0.053)。
  • 该感染总体预后差,53%患者归因于侵袭性真菌感染死亡。

核心结论

  • 伏立康唑联合特比萘芬可能较其他抗真菌方案改善侵袭性L. prolificans感染的治疗结局,但总体病死率仍高。

研究设计与样本

  • FungiScope®罕见侵袭性真菌感染登记库的回顾性病历分析,纳入2008年1月1日至2019年9月9日确诊的41例侵袭性L. prolificans感染患者,来自8个国家。

主要发现

  • 17/40(43%)达治疗反应或疾病稳定,21/40(53%)死于侵袭性真菌感染。
  • 联合抗真菌治疗组28天生存15/24,单药组4/16(p 0.027)。
  • 伏立康唑联合特比萘芬治疗成功10/16(63%,95%CI 35%-85%),其他方案7/24(29%,95%CI 13%-51%,p 0.053)。
  • Kaplan-Meier分析显示伏立康唑联合特比萘芬组中位生存150天,其他方案17天。

临床怎么用

  • 对侵袭性L. prolificans感染,可考虑伏立康唑联合特比萘芬的联合抗真菌方案,但需结合患者具体情况权衡。

局限性

  • 回顾性登记库研究,样本量小(41例),部分分析存在数据缺失(如40例可评估),联合方案比较非随机化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lomentospora prolificans is an emerging cause of serious invasive fungal infections. Optimal treatment of these infections is unknown, although voriconazole-containing treatment regimens are considered the treatment of choice. The objective of this study was to evaluate the role of combination antifungal therapy for L. prolificans infections. METHODS: We performed a retrospective review of medical records of patients with invasive L. prolificans infection diagnosed between 1 January 2008 and 9 September 2019 that were documented in the FungiScope® registry of rare invasive fungal infections. We compared clinical outcomes between antifungal treatment strategies. RESULTS: Over the study period, 41 individuals with invasive L. prolificans infection from eight different countries were documented in the FungiScope® registry. Overall, 17/40 (43%) had treatment response/stable disease and 21/40 (53%) had a fatal outcome attributed to invasive fungal infection. Combination antifungal therapy was associated with increased 28-day survival (15/24 survived versus 4/16 receiving monotherapy; p 0.027) and the combination voriconazole plus terbinafine trended to be associated with higher rates of treatment success (10/16, 63%, 95% CI 35%-85%) compared with other antifungal treatment regimens (7/24, 29%, 95% CI 13%-51%, p 0.053). In Kaplan-Meier survival analysis there was a higher survival probability in individuals receiving the voriconazole/terbinafine combination compared with other antifungal regimens (median survival 150 days versus 17 days). CONCLUSIONS: While overall mortality was high, combination antifungal treatment, and in particular combination therapy with voriconazole plus terbinafine may be associated with improved treatment outcomes compared with other antifungal regimens for the treatment of invasive L. prolificans infections.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Jenks JD, Seidel D, Cornely OA, et al. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019. Clin Microbiol Infect. 2020. PMID: 31972317. doi:10.1016/j.cmi.2020.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。